APA (7th ed.) Citation

E, B., A, D., A, B., D, S., D, D., D, T., . . . S, F. (2026). [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): A randomised, controlled, phase 2 trial. The Lancet. Oncology, 27(6), 699. https://doi.org/10.1016/S1470-2045(26)00108-7

Chicago Style (17th ed.) Citation

E, Baudin, et al. "[177Lu]Lu-dota-tate Versus Sunitinib in Patients with Metastatic Progressive Neuroendocrine Tumours of the Pancreas (OCLURANDOM): A Randomised, Controlled, Phase 2 Trial." The Lancet. Oncology 27, no. 6 (2026): 699. https://doi.org/10.1016/S1470-2045(26)00108-7.

MLA (9th ed.) Citation

E, Baudin, et al. "[177Lu]Lu-dota-tate Versus Sunitinib in Patients with Metastatic Progressive Neuroendocrine Tumours of the Pancreas (OCLURANDOM): A Randomised, Controlled, Phase 2 Trial." The Lancet. Oncology, vol. 27, no. 6, 2026, p. 699, https://doi.org/10.1016/S1470-2045(26)00108-7.